© предоставлено пресс-службой ТГУ
TOMSK, Mar 6 – RIA
Tomsk. Scientists of Tomsk State University (TSU) together
with oncologists develop quick and inexpensive way to predict breast cancer
relapse at the patients with diabetes or a metabolic syndrome which usually
reduce efficiency of chemotherapy, the press service of the university reports
on Monday.
© предоставлено пресс-службой Томского госуниверситета
According to the university, annually about 23
thousand people die of a breast cancer in Russia. This kind of cancer makes
20,4% of all oncological diseases at women. Existence of diabetes or a
metabolic syndrome complicates the course of a disease and reduces efficiency
of chemotherapy. There are no analogs of this technology in the world to
predict risks of a tumoral progression at such patients.
It's noted that the Tomsk scientists suggested to use
chitinase-like proteins as proteins markers, which level indicates existence of
a disease, measuring their level in the tumor tissue samples of patients and
identify their connection with the features of tumor progression at breast
cancer.
"The technology doesn't demand the specialized
medical equipment, and it can be introduced in standard practice of diagnostic
laboratory. Data processing is simple, and the estimated cost of the analysis
is 50 dollars. Duration of the analysis will make one day that allocates it
with considerable advantage before analogs", – the junior researcher Irina
Mitrofanova is quoted in the message.
It is noted that now to predict the efficiency of
chemotherapy and possible relapse of a tumor at early stages of a breast cancer
in the USA and the Netherlands there are diagnostic panels. But they don't
consider associated diseases that reduces efficiency. The cost of one analysis
reaches 2 thousand dollars, it lasts 14 days and demands the expensive
equipment and personnel.
It is added that the research is conducted on the
basis of the Laboratory of transmitting cellular and molecular biomedicine of
TSU and Scientific research institute of oncology. The patent for technology
and its introduction in work of institutions of an oncological profile,
clinical diagnostic laboratories, biomedical centers and research institutes
has to become a result of work of scientists and oncologists.